A number of pyrimidine nucleosides, which may show two hydrogen bonding modes, have been prepared and tested for antiviral activity against a series of viruses. Whilst none of the compounds described showed significant activity against human immunodeficiency virus (HIV), the bicyclic 2'-deoxynucleoside, [2], derived from the base 6H,8H-3,4-dihydropyrimido[4,5-c][1,2]oxazin-7-one, was shown to inhibit herpes simplex virus type 1 (HSV-1) at similar concentrations as BVDU 1 and ACV. Compounds 13, 6· (2-deoxyribofuranosyl)-6H, 8H-2-methyl-3,4-dihydropyrimido[4,5-c][1,2]oxazin-7-one, and 14, N 4-hydroxy-5-(2-chloroethyl)-2'-deoxyuridine, were as active as ACV against varicella-zoster virus (VZV).
Introduction
There have been a large number of derivatives of AZT prepared since it was shown to inhibit (as its 5'-triphosphate) the reverse transcriptase of HIV-1, and one of the aims of this study was to prepare analogues modified at C-4 to give a number of N 4-oxy and N 4-aminocytidine derivatives, and thus take advantage of their amino-imino tautomeric forms. The N 4-hydroxy derivatives related to AZT and AZdU were shown to be inactive (Herdewijn et al., 1988; Czernecki et al., 1993) , and the N 4-methoxy derivative of 3'-azido-2',3'-dideoxycytidine showed only very slight anti-HIV activity. A number of compounds in the N 4-amino series related to AZT were also prepared and tested against HIV-1 and HIV-2, varicella-zoster virus (VZV) and cytomegalovirus (CMV) (Loakes et el., 1995) .
Substituents on the N 4 _ amino group can exist as either the syn or the anti conformer ( Fig. 1) and it has been shown for N 4-methoxycytidine that the methoxy group is syn (Morozov et al., 1982 , Van Meervelt, 1991 , i.e., directed towards the hydrogen bonding face. In order to hold the N 4 -0 substituent in its anti-conformer, the nucleoside based on the ring system 6H, 8H-3,4-dihydropyrimido[4,5-c] [1, 2] oxazin-7-one, 2, designated P, had been prepared and shown to form base pairs more stable than methoxycytosine with both adenine and guanine in oligonucleotide duplexes (Kong Thoo Lin and Brown, 1989) .
N 4-oxycytosine derivatives are predominantly in the tautomeric form shown in 1 and 2; their structures are therefore more akin to thymine derivatives, thus, one of the aims of this work was to prepare the 3'-azido derivative of 2 in order to determine whether it would exhibit anti-HIV activity. In addition the 5-membered ribo-homologue, 3, has been prepared, (Loakes and Brown, 1994) and the antiviral activities of 3, and some of its derivatives against a range of viruses, have been determined.
Results

Chemistry
The 3'-azido-2',3'-dideoxy nucleoside, 7, related to 2, was prepared as shown in Fig. 2. 3',5'·Di-O-toluoyl-5-hydroxyethyl-2'-deoxyuridine (Griengl et al., 1985) , 4a (R=p-Tol, R'=H), was first treated with trityl chloride to protect the free hydroxyl function, to give 4b (R=p-Tol, R'=PhaC), then the toluoyl groups were removed using methanolic ammonia at 50°C overnight to form 4c (R=H, R'=PhaC). The 3'-azido group was introduced as previously described for a related nucleoside (Loakes et al., 1995) to give 5a, (R = PhCO, R'=PhsC), which was detritylated to yield 5b (R = PhCO, R'=H). The free hydroxyl function was then reacted with N-hydroxyphthalimide under Mitsunobu conditions to give the phthalimidooxy derivative la Ib DMSO show conclusively that these compounds exist in the tautomeric form shown, in this solvent. When this sequence of reactions was carried out on the 5-trityloxymethyl compound, 10, derived from 3',5'-di-O-ptoluoyl-5-hydroxymethyl-2'-deoxyuridine, the expected intermediate 11, was obtained, which on deprotection with 80% acetic acid gave the lactone 12 ( Fig. 4 ). Attempts to de-ethoxycarbonylate this derivative failed to give a characterisable product. and N 4-alkoxy-cytidine analogues may exist as two tautomeric forms, anti (1a) or syn (1b). Bicyclic analogues (2 and 3) are constrained in the anti-conformation. Rib = J3-D-ribofuranosyl and dRib = 2-deoxy-J3-D-ribofuranosyl.
3
Antiviral activity HIV. The compounds 2, 3, 5d, 5e and 7, the compounds 9a, 9b and 12 derived from diethyl malonate coupling and the compounds 13 to 16 were each tested against HIV-1 and HIV-2, but found to be either inactive (50% effective concentration: >300IlM) or only slightly active; (EC so of 3'azido-P, 7: 200IlM; EC so of the diethyl malonate derivative of AZT, 9b: 401lM, sc., AZT, 0.016IlM). The 3'-azido derivatives of 5-hydroxymethyl-2' ,3'-dideoxyuridine (Li et al., 1994) , and the 5-methoxymethyl analogue (Tourigny et al., 1989) , both prepared by the method described earlier (Loakes et al., 1995) were also found to be inactive against HIV-1. Loakes and Brown, 1994; compounds 2 and 13, Kong Thoo Lin and Brown, 1989) were tested for antiviral activity against varicella-zoster 7 6 5c, (R = PhCO, R' = NPhth), which was triazolylated (Webb and Matteucci, 1986) to give 6. This, on removal of the benzoyl and phthaloyl groups by reaction with methanolic ammonia, spontaneously cyclized to the desired product, 7.
In addition to the azide, 7, the intermediates 5b and 5c were deprotected to give 5d (5-(2-hydroxyethyl)AZdU, R = H, R' = H) and 5e (5-(2-aminooxyethyl)AZdU, R = H, R' = NH 2 ) , respectively, and each of these compounds were tested for anti-HIV activity. Bischofberger, (1987) demonstrated that a 4-0-triisopropylbenzenesulphonyl (OTPS) group could be displaced from C-4 of pyrimidine nucleosides by carbon nucIeophiles, such as the anion of diethyl malonate. The presence of the two electron withdrawing ester functions such as that in the product, 9, means that the resulting nucleoside might still have the potential to exist as both the exo-and endo-cyclic tautomers. The diethyl malonate derivatives were, therefore, prepared in the 3'-AZdU and AZT series to determine whether they would have any antiviral activity. In this work it was found that a triazole group was displaced from C 4 in both cases by treatment of the more readily available nucleosides 8 (8a, R=H, 8b, R=Me) (Loakes et al., 1995) with diethyl malonate and sodium hydride to give, after deprotection and purification, 9a and 9b (Fig. 3) virus (VZV) and cytomegalovirus (CMV) in human embryonic lung (HEL) cells. Of these compounds none were active against CMV but 13 and 14 were shown to be selective inhibitors of VZV; (EC 5 0 : 1.8-2.8 I-tM, and 2.3-3.9I-tM, respectively). These two compounds showed a comparable anti-VZV activity as aciclovir (ACV) ( Table 1) , but were inferior to BVDU. They required phosphorylation by the viral thymidine kinase (TK) as demonstrated by the lack of activity against TK-VZV strains, (Table 1 ). The activity of 13 is surprizing in view of the fact that the hydrogen bonding face is alkylated. All of the above compounds were found to be inactive against vaccinia virus and vesicular stomatitis virus in human E 6SM cells.
HSV. Compounds 2, 3 and 13-16 were also tested for antiviral activity against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) strains in human EsSM cell cultures: 2 and 14 were found to be markedly active against HSV-1, but they were found to be 7 to 50-fold less "Concentration required to reduce virus plaque formation by 50%. Virus input was 20 PFU. bConcentration required to reduce HEL cell growth by 50%. cApproximately 50% protection was obtained at compound concentrations that ranged between 5 and 150IlM. No complete protection was achieved at the highest concentration tested.
active against HSV-2 ( Table 2) . None of them were active against thymidine kinase (TK-) deficient HSV-1 (B2006 strain), once again suggesting that they require viral TKmediated phosphorylation for antiviral activity. The ribosyl derivatives 3,15 and 16 were inactive against HSV-1 and HSV-2. However, compound 2 proved extremely active, having similar activity to BVDU against HSV-1 and DHPG against HSV-2. The N 4-methyl derivative of 2 (13) was less active against HSV-1 than 2. This may be due to the additional steric bulk of the methyl group on the potential hydrogen bonding face: the presence of the syn methyl group would disrupt hydrogen bonding with the template in the polymerase active site, hence it would be less likely to be accepted as a substrate. The anti-HSV-1 activities of compounds 2, 13 and 14 were of the same order of magnitude when evaluated against HSV-1 in human embryonic lung (HEL) fibroblast cultures. The ribofura- 
3',5'-Di-O-p-to/uoy/-5-(2-trity/oxyethy/)-2'-deoxyuridine 4b
To a solution of the alcohol 4a (Griengl et et., 1985) (5.0g, 10mmol) in pyridine (50ml) trityl chloride (3.0g, 11mmol) was added and the solution stirred at room temperature for 16 h. The solvent was removed and the product worked up and chromatographed, (CHCl a), to give a white foam, yield 6.9g, 93%. none of the compounds described here exhibited any significant anti-HIV activity, some proved to be very effective inhibitors of VZV and HSV-1 and HSV-2. In particular, the 6-membered bicyclic compound, 13, and 5-(2chloroethyl)-N 4-hydroxydeoxycytidine, 14, were found to be as effective inhibitors of varicella-zoster virus as ACV, and the 6-membered bicyclic compound 2 was as efficient an inhibitor of HSV-1 as BVDU. All antivirally active compounds did require phosphorylation by the virus encoded-thymidine kinase to express .their activity. The antiviral potency of the compounds proved to be independent of the cell line used to evaluate their anti-herpetic properties.
Materials and Experimental Procedures: Chemistry
"l-l-n.m.r. spectra were obtained on a Bruker WM-250 spectrometer in d 6-OMSO. Mass spectra were recorded on a Kratos MS890 spectrometer. Ultraviolet spectra in 1% aqueous methanol were recorded on a Perkin-Elmer Lambda 2 spectrophotometer. TIc was carried out on pre-coated F 2 5 4 silica plates and column chromatography with Merck Kieselgel 60 (BOH). Melting points were measured using a Gallenkamp melting point apparatus and are uncorrected. Unless otherwise stated, reactions were worked up as follows: after removal of the solvent, the product was dissolved in chloroform and washed with aqueous sodium bicarbonate solution. The combined organic fractions were dried over sodium sulphate and evaporated. All compounds showed one component by TLC. nosyl derivative 3 seems not to be recognized as a substrate by a virus-induced thymidine kinase, which is in contrast with the previous findings of De Clercq et aI., (1986) and Bernaerts et a/., (1989) on the ribo-derivative of BVDU (BVRU) that was shown to be phosphorylated by the HSV-1-encoded TK. The lack of activity of 3 against HSV-1 and HSV-2 was also confirmed for VZV (Table 2) .
A number of bicyclic pyrimidine analogues have been prepared and tested against a range of viruses. Whilst Minimum inhibitory concentration" (lIM) 
5-(2-Trityloxyethyl)-2'-deoxyuridine, 4c
A solution of 4b (3.0g, 4mmol) in methanolic ammonia (25mI) was stirred at room temperature for 3 days. The solvent was removed and the product chromatographed (CHCI:J5% 
Diisopropyl azodicarboxylate (DIAD) (2.3ml, 11.7mmol) was added to a solution of benzoic acid (1.15g, 9.4mmol), triphenyl phosphine (3.0g, 11.4 mmol) and the nucleoside 4c (4.0g, 7.8mmol) in DMF (100ml) and the solution stirred at room temperature for 15 min. A further portion of triphenyl phosphine (3.0g, 11.4mmol) and DIAD (2.3ml, 11.7mmol) was then added and the solution stirred for a further hour. The 5'-benzoyl-02,3'anhydronucleoside was worked up and chromatographed (CHCI 3/5% MeOH) to give a white solid, yield 3.28g, 70%. lH_ 
3'-Azido-5'-O-benzoyl-5-(2-hydroxyethyl)-2', 3'dideoxyuridine 5b
The trityl compound 5a (2.24g, 3.5mmol) was heated at reflux in 50ml 80% aqueous acetic acid for 30 min. The solvent was removed and the product chromatographed (CHCI:J3% MeOH) to give a yvhite solid, yield 1.01g, 72%. 1H-nmr a(ppm) 2.25 (2H, t, J=6.9 Hz, CH 2), 2.36-2.54 (2H, rn, H-2', H-2"), 3.34- 
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3'-Azido-5'-O-benzoyl-5-(2-phthalimidooxyethyl)-2~3' dideoxyuridine 5c
Triphenyl phosphine (0.85g, 3.2mmol), N-hydroxyphthalimide (0.52g, 3.2mmol) and diethyl azodicarboxylate (0.5ml, 3.2mmol) were added to a solution of the alcohol 5b (0.85g, 2.1mmol), in THF (25ml) and the solution stirred at room temperature for 1 h. This was then worked up and chromatographed (CHCI 3 ) to give a white solid (1.15g, 100%). lH_ nmr a (ppm) 2.41-2.61 (4H, m, CH 2, H-2', H-2"), 4.13-4.21 (3H, m, H-4', CH 20), 4.48-4.59 (2H, m, H-5', H-5"), 4.61-4.66 (1H, m, H-3'), 6.19 (1H, t, J=6.9 Hz, H-1'), 7.45-7.94 (10H, H-6, Ph, Phth), 11.47 (1H, s, NH).
The benzoate 5b (11Omg, 0.27mmol) was stirred at room temperature in 10ml methanolic ammonia for 6 h. The solvent was removed and the product chromatographed (CHCI:J2% MeOH) to give a white solid, yield 70mg, 86%. M. pt. 114-117°C. m/z 156 (M-azido suqar)", 138 C 44.24, H 4.99, N 23.51, C 11 H 14NsOs requires C 44.4, H 5.1, N 23.6 . U.v. Amax 267 (e, 9900), Amin 234.5. lH-nmr a(ppm) 2.24-2.42 (2H, m, H-2', H-2"), 2.36 (2H, rn, CH 2 OH), 3.37-3.49 (2H, rn, CH 2 CH 20H), 3.55-3.66 (2H, m, H-5', H-5"), 3.81-3.84 (1H, rn, H-4'), 4.37-4.41 (1H, m, H-3'), 4.56 (1H, t, OH), 5.21 (1H, t, OH), 6.08 (1H, t, J= 6.8 Hz, H-1'), 7.65 (1H, s, H-6), 11.20 (1H, br, s, NH).
5-(2-Aminooxyethyl}-3'-azido-2',3'-dideoxyuridine, 5e
The phthalimidooxy compound 5c (120mg, 0.22mmol) was stirred at room temperature overnight in methanolic ammonia (10ml). The solvent was removed and the product chro- (1H, t, OH), 6.09 (1H, t, J= 6.1 Hz, H-1'), 7.67 (1H, s, H-6), 11.33 (1H, br, s, NH). 5-(2-phthalimidooxyethyl}-4-(1,2,4-triazolo 
1-(3-Azido-5-0-benzoyl-2,3-dideoxy-B-D-ribofuranosyl)-
Phosphoryl chloride (0.85ml, 9mmol) was added to a solution of 1,2,4-triazole (2.7g, 39mmol) in acetonitrile (25ml) at O°C and the solution stirred for 10 min. Triethylamine (6.5ml, 47mmol) was then added and the solution stirred for a further 15 minutes and then a solution of the nucleoside 5c (1.15g, 2.1mmol) in acetonitrile (20ml) added and the solution stirred at room temperature overnight. The solution was worked up and chromatographed (CHCI 3 ) to give a white foam, yield 0.54g, 43%. "l-l-nrnr a (ppm) 2.45 phosphoryl chloride (0.85ml, 9mmol) 2.75 (2H, m, H-2', H-2"), 3.03-3.33 (2H, m, CH 2), 4. rn, m, rn, CH 20N, m, m, benzoyl CH), m, phthaloyl CH), 8.14, 9.32 (2H, 2 x s, 2 x trlazolo CH), 8.48 (1H, s, [1, 2] oxazin-7-one 7
The triazolo compound, 6, (0.5g, 0.84mmol) was stirred at room temperature overnight in 25ml ammonialdioxan. The solvent was removed and the product chromatographed (CHCIs/1% MeOH) to give the bicyclic 5'-benzoate as a white foam, yield 0.26g, 78%. "l-l-nrnr a (ppm) 2.27-2.45 (4H, m, CH 2, H-2', H-2"), 3.71-3.78 (1H, rn, H-5', H-5"), 4.05-4.08 (1H, m, H-4'), 4.50-4.60 (2H, m, CH 20N), 4.42-4.48 (1H, m, H-3'), 6.14 (1H, t. J= 6.9 Hz, H-1'), 6.79 (1H, s, H"6), 10.65 (1H, s, NH).
The benzoate (0.25g, 0.63mmol) was stirred at room temperature overnight in methanolic ammonia (1Oml). The solvent was removed and the product chromatographed (CHCIs/2% MeOH) to give the bicyclic product 7, as a white foam, yield 113mg, 61%. m/z 294 (M+) Acc. mass found 294. 1061, C 11 H 14N60 4, Dev. -1.5ppm. Analysis Found, C 44.4, H 4.8, N 28.5, C11H14N604 requires C 44.9, H 4.8, N 28.6 
1-(3-Azido-2,3-dideoxy-f3-D-ribofuranosyl)-4-diethoxycarbonylmethylpyrimid-2-one 9a (R=R'=H)
Diethyl malonate (170111, 1.1mmol) was added to a solution of sodium hydride (26mg, 1.1mmol) in THF (5ml) and the solution stirred at room temperature for 30 min. To this was then added a solution of the triazole 8a (R=H) (300mg, 0.55mmol) in THF (5ml) and stirring continued overnight. The product was worked up and chrornatographed (CHCI 3) to give the 5'-trityl derivative as a white foam, yield 284mg, 81%. U.V. A ma x 336.8 (E, 26200), 237.8 (E, 6900), Amin 216, 277.5. pH12 Amax 344.8, 256.8. 1Hnmr a(ppm) 1.16-1.23 (6H, 2 x t, 2 x CH 2 CH 3 ) , 2.34-2.46 (2H, m, H-2', H-2"), 3.28-3.33 (2H, m, H-5', H-5"), 3.84-3.90 (1H, m, H-4'), 4.06-4.19 (4H, 2 x q, 2 X CH~H3)' 4.50-4.63 (1H, m, H-3'), 6.04-6.08 (2H, m, H-6, H-1'), 7.24-7.41 (15H, rn, Trityl CH), 7.60 (1H, d, J=7.6 Hz, H-5), 11.62 (1H, s, NH).
The above trityl compound (280mg, 0.44mmol) was heated at reflux for 30 minutes in 80% aqueous acetic acid (1Oml). The solvent was removed and the product chromatographed (CHCI 3) to give a pale yellow gum, (146mg, 84%). m/z 395 (M+). High res. 395.1443, C16H21Ns070 Dev = 0.5ppm. Analysis Found, C 48.62, H 5.29, N 17.88, C16H21Ns07 requires C 48.6, H 5.4, N 17.7 . 1H-nmr a(ppm) 1.17-1.25 (6H, 2 x t, 2 x CH 2 CH 3 ) , 2. 33-2.45 (2H, m, H-2', H-2"), 3.58-3.63 (2H, m, H-5', H-5"), 3.83-3.88 (1H, m, H-4'), 4.12-4.16 (4H, 2 x q, 2 X CH 2 CH 3), 4. 36-4.38 (1H, m, H-3') , 5.22 (1H, t, OH), 6.05 (1H, t, J= 6.1 Hz, H-1'), 6.26 (1H, d, J= 8.1 Hz, H-6), 7.68 (1H, d, J= 8.1 Hz, H-5), 11.64 (1H, s, NH). 9b (R=CH3, R'=H) Sodium hydride (25mg, 1mmol) was added to a solution of diethyl malonate (165111, 1.1mmol) in THF (15ml) and the solution stirred at room temperature for 30 min. To this was then added the triazole 8b (R=CH 3) (300mg, 0.54mmol) in THF (1Oml)and the solution stirred at room temperature for 1 h. This was worked up as usual and chromatographed (CHCI 3) to give an off-white foam, yield 0.20g, 57%. 1l-l-nrnr a(ppm) 1.14-1.23 (6H, t, J=7 Hz, 2 x CH 2 CH 3 ) , 1.59 (3H, s, CH 3), 2. m, 28 (2H, rn, m, q, J=7 Hz, CH 2 C H 3 ) , m, 6.09 (1H, t, J=6 Hz, m, trityl CH, 11.89 (1H, s, NH) .
1
A solution of the 5'-trityl derivative (180mg, 0.28mmol) in 80% aqueous acetic acid (5ml) was heated at reflux for 30 min. The solvent was removed and the product chromatographed (CHCI 3) to give 9b as a white powder, yield 58mg, 52%. M. pt. 87-89°C. m/z 409 (M+). Analysis Found, C 49.76, H 5.61, N 17.24, C17H23Ns07 requires C 49.9, H 5.7, N 17.1. u.v 1- (1,2,4-triazolo)-5-trityloxymethylpyrimid-2-one 10 Trityl chloride (0.44g, 1.6mmol) was added to a solution of 5hydroxymethyl-3'-azido-2',3'-dideoxyuridine (Li et al., 1994) (0.2g, 0.7mmol) in 25ml pyridine and the solution stirred at room temperature for 2 days. The product was worked up as usual to give the ditrityl compound as a pale brown solid which was not purified, yield 0.61g, 100%. Phosphoryl chloride (0.3ml, 3.2mmol) was added to a suspension of 1,2,4-triazole (0.96g, 13.9mmol) in acetonitrile (25ml) at O°C with vigorous stirring, and after 10 min triethylamine (2.3ml, 16.5mmol) added. The ditrityl compound above (0.38g) in acetonitrile (20ml) was added and the solution stirred at room temperature overnight. The product was worked up as usual and chromatographed (CHCI 3) to give a yellow foam, yield 0.36g, 89%.
"H-nrnr a(ppm) 2.46-2.56 (2H, m, H-2', H-2"), 3.21-3.38 (2H, m, H-5', H-5"), 4. rn, CH 20), rn, m, , 5.95 (1H, t, J=6.1 Hz, H-1'), 7.07-7.47 (31H, m, 2 x trityl CH, H-6), 8.33, 9.28 (2H, 2 x s, triazole CH). -4-[3-azido-2,3-dideoxyribofuranosyl]-2,3,5,6,-tetrahydropyrano[4,5-f]-4H-pyrimid-2,5-dione 12 Diethyl malonate (130111, 0.86mmol) was added to a suspension of sodium hydride (21mg, 0.88mmol) in THF (15ml) and the solution stirred at room temperature for 30 min. To this was added the triazolo compound 10 (0.35g, 0.43mmol) in THF (1OmI) and the solution stirred at room temperature for 2 h. 1H, s, NH) .
3-Ethoxycarbonyl
The ditrityl compound, 11, above (11Omg, 0.12mmol) was heated at reflux in 5ml 80% aqueous acetic acid for 30 min. The solvent was removed and the product chromatographed (CHCIJ5% MeOH) to give the azidolactone 12 as a white foam, yield 35mg, 76%. m/z 238 (M-sugart. High res. 238.0590, C10H1ON20S, Dev. 0 ppm. Analysis Found, C 47.26, H 4.50, N 17.30, C1OH1ON 20S requires C 47.5, H 4.5 N 18.5. u.v 
5-(2-Chloroethyl)-N4-hydroxy-2'-deoxyuridine 14
A solution of N 4-hydroxy-5-(2-chloroethyl)-5',3'-di-O-acetyl-2'deoxyuridine (Kong Thoo Lin and Brown, 1989 ) (150mg, 0.38mmol) in 10ml methanolic ammonia was stirred at room temperature for 6 h. The solution was evaporated and the product chromatographed (CHCIJ10% MeOH) to give a white foam, yield 166mg, 87%. 1H-nmr a(ppm) 1.94-2.09 (2H, m, H-2', H-2"), 2.57-2.68 (2H, m, H-5', H-5"), 3.85-3.90 (1H, m, H-4'), 3.50-3.57 (2H, m, CH 2), 3.69-3.83 (2H, m, CH 2), 4.19-4.21 (1H, m, H-3'), 4.87 (1H, t, 5'-OH), 5.12 (1H, d, 3'-OH), 6.14 (1H, t, J= 6.3 Hz, H-1'),7.01 (1H, s, H-6), 9.32 (1H, s, NOH), 10.12 (1H, s, NH).
Materials and Experimental Procedures: Virology
Varicella-zoster virus (VZV) assays were carried out in human embryonic lung (HEL) cells using TK+ (OKA and YS) and T( 07/1 and YS/R) VZV strains. Virus input was 20 plaque forming units (PFU), and ACV was used as the reference compound. Cytomegalovirus (CMV) assays were carried out in HEL cells using AD-169 and Davis CMV strains. Virus input was 100 PFU. Ganciclovir (DHPG) was used as the reference compound. Herpes simplex virus (HSV) assays were carried out against HSV-1 TK+ (KOS, F and Mcintyre) and HSV-2 (G and Lyons) and against HSV-1 TK-(B2006) and HSV-1 TK-ITK+ (VMW1837) in embryonic skin-muscle (E 6SM) and human embryonic lung (HEL) cell cultures. BVDU, ribavirin, DHPG and ACV were used as reference compounds. HIV-1 assays were carried out in C8166 cells with the HIV-1 (Ills) strain. Cell viability and cytotoxicity were measured by MTT-Formazan and the gp120 content in the infected cell culture supernatants was estimated by ELISA. HIV-1 (Ills) and HIV-2 (ROD) assays were also performed in MT-4 and CEM cells at low, 10 TCID so (50% tissue culture infective dose) and at 100 TCID so (data not shown).
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